Contrasting Organovo (ONVO) & Editas Medicine (EDIT)Week HeraldIt is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex … Continue reading
|
Another Gene Therapy Breakthrough Against Hemophilia
U.S. News & World Report SATURDAY, Dec. 9, 2017 (HealthDay News) — Coming just days after reports of a gene therapy that pushed the bleeding disorder hemophilia B into remission, new research suggests the same could be true for adults with the “A” form of the disease. That’s … Hemophilia Gene Therapy Global Market Sees Promising Growth during 2017-2022: Novo Nordisk A/S, PfizerMilTech |
STAT |
BioMarin’s gene therapy reduces bleeding in hemophilia patients, making Roche look over its shoulder
STAT ATLANTA — Hemophilia researchers representing Roche (RHBBY 1) and BioMarin Pharmaceuticals (BMRN 2) shared a dais Saturday during a media briefing at the American Society of Hematology (ASH) annual meeting. That’s fitting because both companies are … |
The Oakland Press |
Gene therapy shows promise against blood-clotting disease
The Oakland Press Gene therapy shows promise against blood-clotting disease. This Saturday, Dec. 2, 2017 photo provided by Jay Konduros, left, shows him and his brother, Bill, at Jay’s home in Cambridge, Ontario, Canada. The brothers, who have hemophilia, were involved … |
FierceBiotech |
‘Epigenetic CRISPR’ edits DNA without cutting it | FierceBiotech
FierceBiotech A Salk Institute team created a form of CRISPR/Cas9 that activates specific genes without making breaks in the DNA, which can cut down on harmful side effects. CRISPR/Cas9 can reverse multiple diseases in miceScience News Diabetes and muscular dystrophy could be treated effectively with modified Crispr genetic engineering techniqueThe Independent CRISPR/Cas9 Edits Epigenome with Therapeutic EfficiencyGenetic Engineering & Biotechnology News |